Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for the Prevention of Chronic Migraine
NCT07729462Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2026
- Primary completion
- Oct 2028
- Countries
- 2
01
Overview
A Phase 3 trial of rimegepant in chronic migraine, sponsored by Pfizer. Started Aug 2026; status: recruiting.
02
Drugs
rimegepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT07729462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729462.